Scientists at Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have synthesized kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.

Shenzhen Zhongge Biotechnology Co. Ltd. has identified kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.

Simcere Zaiming Pharmaceutical Co. Ltd. has identified kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.

Genescience Pharmaceuticals Co. Ltd. has described fused ring kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.

Xuanzhu Pharma Co. Ltd. has synthesized kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.

Volastra Therapeutics Inc. has entered into partnerships with Microsoft Corp., Function Oncology Inc. and Tailor Bio Ltd. with the goal of expanding the potential use of its KIF18A inhibitors.

Kinesin-like protein KIF18A inhibitors have been reported in a Humanwell Healthcare (Group) Co. Ltd. patent and are described as potentially useful for the treatment of atopic dermatitis, autoimmune disease, cancer, Crohn’s disease, psoriasis and ulcerative colitis.

Kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer have been detailed in a recent GT Apeiron Therapeutics patent.

Humanwell Healthcare (Group) Co. Ltd. has identified new kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer, psoriasis, atopic dermatitis, autoimmune diseases and inflammatory bowel disease.